AbbVie Inc. (ABBV)

90.10
1.80 2.00
NYSE : Health Technology
Prev Close 88.31
Open 87.78
Day Low/High 85.96 / 90.29
52 Wk Low/High 77.50 / 125.86
Volume 9.13M
Avg Volume 5.81M
Exchange NYSE
Shares Outstanding 1.50B
Market Cap 134.91B
EPS 3.30
P/E Ratio 18.30
Div & Yield 4.28 (4.00%)

Latest News

AbbVie To Present At The Evercore ISI Conference

AbbVie To Present At The Evercore ISI Conference

NORTH CHICAGO, Ill., Nov.

Hagens Berman Reminds AbbVie (NYSE: ABBV) Investors Of Ongoing Investigation Of AbbVie's Humira Sales Practices

Hagens Berman Reminds AbbVie (NYSE: ABBV) Investors Of Ongoing Investigation Of AbbVie's Humira Sales Practices

SAN FRANCISCO, Nov. 9, 2018 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP reminds investors in AbbVie Inc.

AbbVie Characterizes Evolving Hepatitis C (HCV) Patient Landscape In The United States Using Comprehensive Dataset

AbbVie Characterizes Evolving Hepatitis C (HCV) Patient Landscape In The United States Using Comprehensive Dataset

- New MappingHepC.com website provides HCV community an easily accessible source of chronic HCV epidemiology data

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In AbbVie Inc. Of Class Action Lawsuit And Upcoming Deadline - ABBV

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In AbbVie Inc. Of Class Action Lawsuit And Upcoming Deadline - ABBV

NEW YORK, Nov. 7, 2018 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AbbVie Inc.

AbbVie Announces HUMIRA® (adalimumab) Global Patent License With Momenta

AbbVie Announces HUMIRA® (adalimumab) Global Patent License With Momenta

NORTH CHICAGO, Ill., Nov.

I Don't Know Why, but There Is No Enthusiasm for This Market

The gloom is so thick you can cut it with a knife.

Nibble on This Bearish Strategy in Shake Shack: Market Recon

Nibble on This Bearish Strategy in Shake Shack: Market Recon

SHAK beat expectations for both EPS and revenue, but same-store sales decreased. Here is how I would play it.

AbbVie Reports Third-Quarter 2018 Financial Results

AbbVie Reports Third-Quarter 2018 Financial Results

- Reports Third-Quarter Diluted EPS of $1.81 on a GAAP Basis; Adjusted Diluted EPS of $2.14 Reflects Growth of 51.8 Percent

A One-Two Punch to the Bears: Cramer's 'Mad Money' Recap (Thursday 11/1/18)

A One-Two Punch to the Bears: Cramer's 'Mad Money' Recap (Thursday 11/1/18)

Jim Cramer's been saying that that if the Fed or the president blink in their wars against inflation and China you could have an up day. That's what we got.

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Once the safest stocks in the book, the big-cap drug companies are now toxic.

AbbVie Receives European Commission Approval Of VENCLYXTO® (venetoclax) Plus Rituximab For The Treatment Of Patients With Chronic Lymphocytic Leukemia Who Have Received At Least One Prior Therapy

AbbVie Receives European Commission Approval Of VENCLYXTO® (venetoclax) Plus Rituximab For The Treatment Of Patients With Chronic Lymphocytic Leukemia Who Have Received At Least One Prior Therapy

- The approval is based on the MURANO Phase 3 clinical trial, in which VENCLYXTO® plus rituximab reduced the risk of disease progression or death by 83 percent and overall survival was prolonged compared to bendamustine in combination with rituximab, a standard of care chemoimmunotherapy regimen¹

AbbVie Announces Positive Results From CLL14, A Phase 3 Trial Evaluating A Venetoclax Combination As First-Line Therapy With A Fixed Duration Of Treatment In Patients With Chronic Lymphocytic Leukemia

AbbVie Announces Positive Results From CLL14, A Phase 3 Trial Evaluating A Venetoclax Combination As First-Line Therapy With A Fixed Duration Of Treatment In Patients With Chronic Lymphocytic Leukemia

- Randomized Phase 3 trial met primary endpoint, demonstrating patients treated with venetoclax plus obinutuzumab had superior progression-free survival (PFS) compared to patients treated with standard of care obinutuzumab plus chlorambucil

Be Ready to Ride the Dividend on Gilead Sciences

Be Ready to Ride the Dividend on Gilead Sciences

There are no catalysts to drive the stock price higher, so for now, Gilead is simply a cheap stock with a nice dividend.

AbbVie Becomes #64 Most Shorted S&P 500 Component, Replacing Kimco Realty

AbbVie Becomes #64 Most Shorted S&P 500 Component, Replacing Kimco Realty

The most recent short interest data has been released for the 10/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Clorox, Sirius XM Radio, New Relic: 'Mad Money' Lightning Round

Clorox, Sirius XM Radio, New Relic: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Clorox, Sirius XM Radio, New Relic, AbbVie, ShotSpotter and more.

How Much Tighter?: Cramer's 'Mad Money' Recap (Wednesday 10/3/18)

How Much Tighter?: Cramer's 'Mad Money' Recap (Wednesday 10/3/18)

Jim Cramer asks if the Fed is trying so hard to cool the economy that it could crush wage growth.

Tech Doesn't Have Good Defense: Cramer's 'Mad Money' Recap (Thursday 9/6/18)

Tech Doesn't Have Good Defense: Cramer's 'Mad Money' Recap (Thursday 9/6/18)

Jim Cramer, celebrating the opening of the NFL season, says this is just another day of total tech mayhem.

United Parcel Service, TJX Companies: 'Mad Money' Lightning Round

United Parcel Service, TJX Companies: 'Mad Money' Lightning Round

Jim Cramer takes a look at United Parcel Service, TJX Companies, Anheuser-Busch InBev, Fiat Chrysler, AbbVie, Nvidia, Excelixis, Bank of America, Endo Pharmaceutical and more.

AbbVie, Greendot, Sherwin-Williams: 'Mad Money' Lightning Round

AbbVie, Greendot, Sherwin-Williams: 'Mad Money' Lightning Round

Jim Cramer takes a look at AbbVie, Greendot, Sherwin-Williams, Visteon, TransEnterix, Duke Energy, Buckeye Partners, Arch Coal and more.

More Than One Way to Win: Cramer's 'Mad Money' Recap (Thursday 8/9/18)

More Than One Way to Win: Cramer's 'Mad Money' Recap (Thursday 8/9/18)

Jim Cramer says that in good markets there are always multiple ways for investors to win.

ABBVIE LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In AbbVie, Inc. To Contact The Firm

ABBVIE LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In AbbVie, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AbbVie, Inc.

AbbVie's Upadacitinib Shows Significant Improvements In Physical Function, Pain And Quality Of Life As A Monotherapy In Patients With Rheumatoid Arthritis In Phase 3 Patient-Reported Outcomes Data

AbbVie's Upadacitinib Shows Significant Improvements In Physical Function, Pain And Quality Of Life As A Monotherapy In Patients With Rheumatoid Arthritis In Phase 3 Patient-Reported Outcomes Data

- Upadacitinib monotherapy showed improvements in physical function, a measure that assesses patients' ability to perform daily activities and level of disability, versus methotrexate at week 14[1]

Positive Phase 2b Data For AbbVie's Upadacitinib Show Significant Induction Of Clinical Remission And Response In Patients With Ulcerative Colitis

Positive Phase 2b Data For AbbVie's Upadacitinib Show Significant Induction Of Clinical Remission And Response In Patients With Ulcerative Colitis

- In U-ACHIEVE, upadacitinib (15/30/45 mg, once daily) met the primary endpoint of clinical remission (per Adapted Mayo Score) and all ranked secondary endpoints, including endoscopic improvement, clinical remission (per Full Mayo Score) and clinical response, in patients with moderately to severely active ulcerative colitis[1]

AbbVie Announces Global Resolution Of HUMIRA® (adalimumab) Patent Disputes With Fresenius Kabi

AbbVie Announces Global Resolution Of HUMIRA® (adalimumab) Patent Disputes With Fresenius Kabi

- Agreements Provide Non-Exclusive License to Fresenius Kabi for HUMIRA-Related Intellectual Property in the U.S. Effective September 30, 2023, and in Other Markets on Different Dates

AbbVie And Morphic Therapeutic Announce Collaboration Targeting Fibrotic Diseases

AbbVie And Morphic Therapeutic Announce Collaboration Targeting Fibrotic Diseases

Collaboration leverages Morphic's unique platform for developing oral integrin drugs and AbbVie's global development and commercialization capabilities

AbbVie Announces Supplemental New Drug Application Accepted For Priority Review By U.S. FDA For IMBRUVICA® (ibrutinib) In Combination With Obinutuzumab (GAZYVA®) For Previously Untreated Chronic Lymphocytic Leukemia (CLL)

AbbVie Announces Supplemental New Drug Application Accepted For Priority Review By U.S. FDA For IMBRUVICA® (ibrutinib) In Combination With Obinutuzumab (GAZYVA®) For Previously Untreated Chronic Lymphocytic Leukemia (CLL)

- If granted, IMBRUVICA plus obinutuzumab could become the first chemotherapy-free, anti-CD20 combination approved by the FDA for first-line CLL treatment

The Law Offices Of Howard G. Smith Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against AbbVie Inc. (ABBV)

The Law Offices Of Howard G. Smith Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against AbbVie Inc. (ABBV)

Law Offices of Howard G. Smith reminds investors of the  October 22, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased AbbVie Inc.

TheStreet Quant Rating: B- (Buy)